齐拉西酮辅助治疗青春期双相情感障碍I型躁狂发作的疗效探讨

Clinical effects investigation of ziprasidone adjuvant therapy on type I manic episode of bipolar disorder in puberty

目的探讨齐拉西酮辅助治疗青春期双相情感障碍I型躁狂发作的临床效果及安全性。方法选取该院近期收治青春期双相情感障碍I型躁狂发作患者160例,采用随机数字表法分为对照组(80例)和试验组(80例),分别给予碳酸锂单用治疗和在此基础上加用齐拉西酮辅助治疗;比较两组患者临床疗效,治疗前后Bech-Rafaelsen躁狂量表(BRMS)评分、临床总体印象疾病严重度量表-双向障碍版(CGI-s-BP)及不良反应发生情况等。结果试验组患者临床治疗显效率和总有效率均显著优于对照组,差异有统计学意义(P<0.05);试验组患者治疗后BRMS评分和CGI-s-BP评分均显著优于对照组和治疗前,差异有统计学意义(P<0.05);两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论齐拉西酮辅助治疗青春期双相情感障碍I型躁狂发作可显著缓解病情,减轻躁狂症状,且未增加不良反应发生风险。

[ Objective ] To investigate clinical effects and safety of ziprasidone adjuvant therapy on type I manic episode of bipolar disorder in puberty. [ Methods ] A total of 160 children with type I manic episode of bipolar disorder in puberty were chosen in our hospital in recent years and randomly divided into two groups including control group （80 children） with lithium carbonate used alone and experimental group （80 children） with ziprasidone adjuvant therapy on the basis of control group; the clinical efficiency, the Bech-Rafaelsen Mania Rating Scale （BRMS） and clinical global impression score for disease severity scale - bipolar disorder Version （CGI-s-BP） before and after treatment and incidence of adverse effects of both groups were compared. [ Results ] The clinical efficacy of experi- mental group was significantly better than that of control group （P 〈 0.05）. The BRMS scores and CGI-s-BP scores of experimental group after treatment was significantly better than those of control group and those before treatment （P 〈 0.05）. There was no significant difference in the incidence of adverse effects between two groups （P 〈 0.05）. [ Conclusions ] Ziprasidone adjuvant therapy on type I manic episode of bipolar disorder in puberty can efficiently alleviate disease condition and mania degree, and not increase the risk of adverse reaction.